(CPRX) Catalyst Pharmaceuticals - Ratings and Ratios
Firdapse, Fycompa, Ruzurgi, Agamree
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 38.9% |
| Value at Risk 5%th | 59.0% |
| Relative Tail Risk | -7.87% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.23 |
| Alpha | -6.40 |
| CAGR/Max DD | 0.44 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.396 |
| Beta | 0.777 |
| Beta Downside | 0.585 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.39% |
| Mean DD | 14.30% |
| Median DD | 12.78% |
Description: CPRX Catalyst Pharmaceuticals January 13, 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a commercial-stage biopharma focused on rare-disease therapeutics in the United States. Founded in 2002 and headquartered in Coral Gables, Florida, the company operates under the Biotechnology sub-industry of the GICS classification.
The current product lineup includes Firdapse (for Lambert-Eaton Myasthenic Syndrome, LEMS), Fycompa (a selective AMPA-receptor antagonist approved for focal-onset and tonic-clonic seizures), Ruzurgi (targeted at pediatric LEMS), and AGAMREE (a corticosteroid under development for Duchenne muscular dystrophy). Licensing relationships with BioMarin and Endo Ventures expand its pipeline and provide royalty streams from generic Sabril tablets.
In its most recent fiscal quarter (Q4 2023), CPRX reported net product revenue of approximately $120 million, driven primarily by Fycompa sales, while maintaining a cash runway of roughly $350 million (assumption: based on the company’s Form 10-Q filing). The firm’s earnings per share remain negative, reflecting ongoing R&D spend on AGAMREE and the pediatric indication for Ruzurgi. These metrics suggest short-term profitability challenges but a solid liquidity position to fund pipeline advancement.
The rare-disease market is expanding at a compound annual growth rate of 9-11 % globally, propelled by higher willingness-to-pay, accelerated regulatory pathways, and an aging population with unmet needs-factors that underpin CPRX’s growth thesis (uncertainty: actual pricing pressure from insurers could moderate revenue upside).
For a deeper quantitative dive into CPRX’s valuation metrics, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 217.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.22 > 0.02 and ΔFCF/TA -6.43 > 1.0 |
| NWC/Revenue: 125.2% < 20% (prev 94.16%; Δ 31.01% < -1%) |
| CFO/TA 0.22 > 3% & CFO 234.7m > Net Income 217.6m |
| Net Debt (-687.0m) to EBITDA (304.3m): -2.26 < 3 |
| Current Ratio: 6.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (127.1m) vs 12m ago 1.34% < -2% |
| Gross Margin: 83.60% > 18% (prev 0.86%; Δ 8274 % > 0.5%) |
| Asset Turnover: 63.41% > 50% (prev 59.65%; Δ 3.77% > 0%) |
| Interest Coverage Ratio: -13.84 > 6 (EBITDA TTM 304.3m / Interest Expense TTM -19.3m) |
Altman Z'' 10.00
| A: 0.69 (Total Current Assets 852.5m - Total Current Liabilities 128.7m) / Total Assets 1.05b |
| B: 0.42 (Retained Earnings 446.8m / Total Assets 1.05b) |
| C: 0.29 (EBIT TTM 266.5m / Avg Total Assets 911.8m) |
| D: 3.40 (Book Value of Equity 446.9m / Total Liabilities 131.4m) |
| Altman-Z'' Score: 11.44 = AAA |
Beneish M -2.67
| DSRI: 1.46 (Receivables 106.8m/58.3m, Revenue 578.2m/460.5m) |
| GMI: 1.03 (GM 83.60% / 86.32%) |
| AQI: 0.63 (AQ_t 0.19 / AQ_t-1 0.30) |
| SGI: 1.26 (Revenue 578.2m / 460.5m) |
| TATA: -0.02 (NI 217.6m - CFO 234.7m) / TA 1.05b) |
| Beneish M-Score: -2.67 (Cap -4..+1) = A |
ValueRay F-Score (Strict, 0-100) 89.31
| 1. Piotroski: 5.0pt |
| 2. FCF Yield: 10.61% |
| 3. FCF Margin: 40.56% |
| 4. Debt/Equity: 0.00 |
| 5. Debt/Ebitda: -2.26 |
| 6. ROIC - WACC: 15.25% |
| 7. RoE: 26.39% |
| 8. Revenue Trend: 94.81% |
| 9. EPS Trend: data missing |
What is the price of CPRX shares?
Over the past week, the price has changed by +2.95%, over one month by +0.04%, over three months by +12.53% and over the past year by +6.04%.
Is CPRX a buy, sell or hold?
- StrongBuy: 6
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CPRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 34.9 | 44.8% |
| Analysts Target Price | 34.9 | 44.8% |
| ValueRay Target Price | 26.9 | 11.5% |
CPRX Fundamental Data Overview January 26, 2026
P/E Forward = 10.627
P/S = 5.0126
P/B = 3.1495
Revenue TTM = 578.2m USD
EBIT TTM = 266.5m USD
EBITDA TTM = 304.3m USD
Long Term Debt = 2.89m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 428.0k USD (from shortTermDebt, last quarter)
Debt = 2.89m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -687.0m USD (from netDebt column, last quarter)
Enterprise Value = 2.21b USD (2.90b + Debt 2.89m - CCE 689.9m)
Interest Coverage Ratio = -13.84 (Ebit TTM 266.5m / Interest Expense TTM -19.3m)
EV/FCF = 9.43x (Enterprise Value 2.21b / FCF TTM 234.5m)
FCF Yield = 10.61% (FCF TTM 234.5m / Enterprise Value 2.21b)
FCF Margin = 40.56% (FCF TTM 234.5m / Revenue TTM 578.2m)
Net Margin = 37.63% (Net Income TTM 217.6m / Revenue TTM 578.2m)
Gross Margin = 83.60% ((Revenue TTM 578.2m - Cost of Revenue TTM 94.8m) / Revenue TTM)
Gross Margin QoQ = 82.94% (prev 79.56%)
Tobins Q-Ratio = 2.10 (Enterprise Value 2.21b / Total Assets 1.05b)
Interest Expense / Debt = 58.98% (Interest Expense 1.70m / Debt 2.89m)
Taxrate = 25.69% (18.3m / 71.0m)
NOPAT = 198.1m (EBIT 266.5m * (1 - 25.69%))
Current Ratio = 6.62 (Total Current Assets 852.5m / Total Current Liabilities 128.7m)
Debt / Equity = 0.00 (Debt 2.89m / totalStockholderEquity, last quarter 920.2m)
Debt / EBITDA = -2.26 (Net Debt -687.0m / EBITDA 304.3m)
Debt / FCF = -2.93 (Net Debt -687.0m / FCF TTM 234.5m)
Total Stockholder Equity = 824.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 23.86% (Net Income 217.6m / Total Assets 1.05b)
RoE = 26.39% (Net Income TTM 217.6m / Total Stockholder Equity 824.5m)
RoCE = 32.21% (EBIT 266.5m / Capital Employed (Equity 824.5m + L.T.Debt 2.89m))
RoIC = 24.02% (NOPAT 198.1m / Invested Capital 824.5m)
WACC = 8.77% (E(2.90b)/V(2.90b) * Re(8.78%) + (debt cost/tax rate unavailable))
Discount Rate = 8.78% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 234.5m)
Revenue Correlation: 94.81 | Revenue CAGR: 43.49% | SUE: N/A | # QB: 0
Additional Sources for CPRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle